Article info
PDFOriginal research
Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix
- Correspondence to Dr Michael Frumovitz, Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77057, USA; mfrumovitz{at}mdanderson.org
Citation
Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix
Publication history
- Received May 21, 2020
- Revision received June 22, 2020
- Accepted June 29, 2020
- First published July 29, 2020.
Online issue publication
November 15, 2020
Article Versions
- Previous version (7 September 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.